A Phase II Study of the BRAF Inhibitor Encorafenib in Combination With the MEK Inhibitor Binimetinib in Patients With BRAFV600E-mutant Metastatic Non-small Cell Lung Cancer
Latest Information Update: 12 Mar 2024
At a glance
- Drugs Binimetinib (Primary) ; Encorafenib (Primary) ; Docetaxel
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- Acronyms ENCO-BRAF
- 06 Mar 2024 Planned primary completion date changed from 1 Feb 2024 to 1 Sep 2024.
- 15 Mar 2022 Planned number of patients changed from 144 to 119.
- 15 Mar 2022 Planned End Date changed from 1 Mar 2025 to 1 Mar 2026.